Aktie A1W39X SOPHIRIS BIO, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Sophiris Bio, Inc. Other OTC

Aktien

A1W39X

CA83578Q2099

SPHS

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Swiss franc rises to six year high as central bank stands back
Sophiris Bio : Swiss c.bank diverges from peers to stick with ultra-loose monetary course
Sophiris Bio : Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights
Sophiris Bio : Reports Second Quarter 2016 Financial Results and Key Business Highlights
Sophiris Bio : Reports First Quarter 2016 Financial Results and Key Business Highlights
Sophiris Bio : To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
Sophiris Bio, Inc. Announces Joseph L. Turner Would Not Be Stand for Re-Election at the Annual General Meeting
Sophiris Bio, Inc. Auditor Raises 'Going Concern' Doubt
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
Sophiris Bio, Inc. Reports Encouraging Preliminary Data from Phase 2A Proof of Concept Study in Localized Prostate Cancer
Sophiris Bio, Inc. announced that it has received $2.8 million in funding from Aspire Capital Partners, LLC
Sophiris Bio : Reports Third Quarter Financial Results and Business Highlights
Sophiris Bio : Phase 3 BPH Study Successfully Meets Primary Endpoint
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
Sophiris Bio : Reports Second Quarter Financial Results
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Sophiris Bio : to Present at the LD Micro Invitational Conference
Sophiris Bio : Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study
Sophiris Bio, Inc. Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1W39X Aktie
  4. A1W39X Aktie
  5. Nachrichten Sophiris Bio, Inc.
  6. Andere Sprachen